Akari Therapeutics
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
401 E Jackson St Ste 3300, Tampa, Florid...Phone Number
+44 2080040261Website
www.akaritx.comRevenue
-Stock Symbol
AKTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan, is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.Explore more
Akari Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akari Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Akari Therapeutics launches new products
Funding: Get notified immidiatlly once Akari Therapeutics has new funding data
Earning: See what the market has to say on Akari Therapeutics recently announced quarterly report
Check out if Akari Therapeutics is spiking on competitors!
Click to see if Akari Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Akari Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Akari Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Akari Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Akari Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Akari Therapeutics
Compare insights from companies similar to Akari Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Akari Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Akari Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Akari Therapeutics.
Akari Therapeutics financials insights
Gather financial insights about Akari Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Share Placement
$4.5M
2020
Share Placement
$6M
Share Placement
$9.5M
2024
Share Placement
$2M
Share Placement
$7.6M
2026
Stock/Share Issuance
$5.5M
Akari Therapeutics Tech Stack
A closer look at the technologies used by Akari Therapeutics
See more technologies
Most Recent Scoops
Funding
Akari Therapeutics has secured $5.5 million in Share Issuance funding. Investors were not disclosed.
Funding
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Bioengineering, Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Event
Events, Research & Development, Pharmaceuticals
Akari Therapeutics News & Media
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available hereAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical modelsAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akari Therapeutics
Sign Up For FreeTo access detailed company insights
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug... Read More
